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Abstract
Purpose Tomeasure the effects of an unplanned, sudden cessation of treatment in an unselected group of patients with chronic painful
LUTS managed with protracted antimicrobial treatment and to report these observational data collected from a cross-over process.
Materials and methods The imposition of a guideline resulted in the immediate cessation of antibiotic treatment in a cohort of patients
with chronic painful LUTS and microscopic pyuria. Patients were assessed before treatment withdrawal, whilst off treatment, and
following reinstatement. Outcome measures included a validated symptom score, microscopic enumeration of urinary white cells and
uroepithelial cells, and routine urine culture.
Results These patients had reported treatment-resistant, painful LUTS for a mean of 6.5 years before treatment at this centre.
Treatment was stopped in 221 patients (female = 210; male = 11; mean age = 56 years; SD = 17.81). Sixty-six per cent of women
were post-menopausal. After unplanned treatment cessation, 199 patients (90%; female = 188; male = 9) reported deterioration.
Eleven patients required hospital care in association with disease recurrence, including acute urinary tract infection (UTI) and
urosepsis. Symptom scores increased after cessation and recovered on reinitiating treatment (F = 33; df = 2; p < 0.001). Urinary
leucocyte (F = 3.7; df = 2; p = 0.026) and urothelial cells counts mirrored symptomatic changes (F = 6.0; df = 2; p = 0.003).
Routine urine culture results did not reflect changes in disease status.
Conclusion These data support the hypothesis that treating painful LUTS associated with pyuria with long-term antimicrobial
courses, despite negative urine culture, is effective. The microscopy of fresh unspun, unstained urine to count white cells and
epithelial cells offers a valid method of monitoring disease. An unplanned cessation of antibiotic therapy produced a resurgence
of symptoms and lower urinary tract inflammation in patients with chronic LUTS, supporting an infective aetiology below the
level of routine detection.
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Introduction
Recalcitrant chronic bladder pain and symptoms of recurrent
cystitis in patients with negative urinalysis present a worrying
management problem. The treatment of painful lower urinary
tract symptoms (LUTS) is a significant challenge, and there
are few quality data to guide clinicians. The evidence for oral
or intravesical therapies for painful bladder symptoms is poor
[1]. Cystodistension and urethral dilation are also deployed
without evidence to support their utility [2–4]. Patients with
recurrent, acute symptoms of cystitis and negative urinalysis
are often exposed to multiple, short courses of antibiotics in
primary care without evidence of benefit [5].
While there are published guidelines for managing acute
and recurrent urinary tract infection (UTI) [6], there are none
for patients who may be suffering a chronic form of the dis-
ease. Recently, we published data describing our experience
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treating women with chronic painful LUTS for a mean dura-
tion of 6 years prior to presentation to our clinic. These pa-
tients had been exposed to conventional therapies without a
resolution of symptoms. Data were gathered from 624 patients
over 10 years. Given microscopic pyuria and symptoms, we
presumed an infectious cause even in the face of negative
dipstick urinalysis and urine cultures, as these tests lack sen-
sitivity and fail to detect infective organisms in bona fide
disease [7, 8]. This previous report described the evolution
of a simple management regimen using first-generation, nar-
row-spectrum, urinary antibiotics combined with methena-
mine hippurate, guided by symptom palliation and the resolu-
tion of pyuria [9]. The study demonstrated that treatment was
associated with symptomatic improvement and the resolution
of biomarkers of infection. There were few treatment-
emergent adverse events (AEs) and no significant increase in
antibiotic-resistant isolates. These data are being employed to
develop a randomised trial (RCT).
This novel approach requires clinic-based fresh urine mi-
croscopy to quantify pyuria, full doses of urinary antibiotic,
protracted treatment periods and careful safety monitoring [9].
Although some patients (20%) could be discharged after only
6 months, we found that it took an average of 383 days [95%
confidence interval (CI) = 337–428] to achieve symptom res-
olution (mean reduction in validated symptom score = 70%)
without the need for further antibiotic treatment. A reduction
in symptoms and pyuria associated with antibiotic treatment,
followed by deterioration in both measures on early treatment
cessation, provided additional cogent observational evidence
of efficacy.
Despite positive preliminary data, this therapeutic ap-
proach contravenes guidelines for treating acute urinary
infection and recognised treatment regimens for recurrent
UTI [10]. It also defies antibiotic stewardship policies [11,
12]. The evolution of this treatment method has been sup-
ported by a long-running translational research pro-
gramme and basic scientific activity at University
College London. As such, the clinical approach has been
founded on peer-reviewed preclinical and clinical research
in addition to the systematic collection of efficacy and
safety data through surveillance. Nevertheless, the nature
of the treatment generated understandable concern
amongst medical managers within the host NHS trust
and primary care commissioners.
In September 2015 a patient being managed with
nitrofurantoin, having failed numerous attempts to withdraw
this agent over 30 months, developed a rare, acute eosinophil-
ic pneumonitis, which is reported to occur only during the first
6 months of treatment [13]. Nitrofurantoin was stopped, and
the occurrence was reported to our trust, in line with local
safety monitoring procedures. This one serious adverse event
(SAE) occurred amongst a cohort of 624 patients during
273,762 treatment days. There were 475 total AEs during this
period, managed with medication withdrawal or modification
as outpatients.
In response to this SAE, the trust medical management
imposed prescribing restrictions limiting treatment to short-
course antibiotic therapy recommended by guidelines for
acute UTI. This imposition effectively suspended the service,
and treatment was stopped in 221 patients on long-term regi-
mens. Although the service reopened 5 weeks later, this sud-
den suspension tested the hypothesis, supported by previous
data, that premature cessation of long-term antibiotic therapy
results in disease regression. This article reports the outcomes
that ensued from this event.
Methods
Our diagnosis of UTI rests on symptoms, signs, and micro-
scopic pyuria. Without the latter we do not initiate antibiotic
treatment. We combine methenamine hippurate, a bactericidal
urinary antiseptic, with a full-dose, first-generation, narrow-
spectrum urinary antibiotic. Antibiotic selection is based on
symptomatic response and a reduction in pyuria along with
drug tolerance. Cefalexin is favoured as first-line therapy be-
cause previous outcome data showed this first-generation
cephalosporin to evince the least side effect record of all of
the agents that we had used. It is known to have the lowest
Clostridium difficile incidence of the antibiotics [14].
Trimethoprim and nitrofurantoin were second- and third-
choice agents. We continue treatment until symptom control
is optimal and pyuria has cleared before testing treatment
withdrawal; we restart the treatment if relapse occurs.
Usually, more than one cycle is required to achieve lasting
symptom resolution off treatment [9].
The clinical service was suspended for 5 weeks from 21
October 2015. When these restrictions were lifted, we
contacted patients who had stopped treatment. We identified
those who reported symptom deterioration and wherever pos-
sible assessed them at the centre as a priority. We measured
their symptoms, using a validated measure [15], and urine
samples were examined immediately by microscopy using a
haemocytometer to quantify leucocytes and shed epithelial
cells. Previous work using an antibody against the specific
urothelial marker protein uroplakin-3 has shown that the ma-
jority of epithelial cells present in the urine specimens of these
patients originate from the bladder, they are not contaminants
from the vulva or vagina [16]. In the majority of cases, disease
recurrence, indicated by worsening symptoms and pyuria,
motivated reintroduction of treatment. The clinic suspension
permitted the collection of data before treatment cessation,
whilst off treatment following cessation and after treatment
was restarted.
The following variables were collected: 24-h frequency,
24-h incontinence episodes, lower urinary tract pain, urinary
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urgency, voiding symptoms and stress urinary incontinence
[15]. If attending the centre, urinalysis included urinary leu-
cocyte and epithelial cell counts, quantified from fresh urinary
microscopy, and routine urine culture. These data were report-
ed at three time points: (1) whilst on treatment prior to the
closure; (2) whilst off treatment after the closure; (3) after
recommencing treatment. Data reported after restarting treat-
ment were captured from the last consultation within
12 months of the cessation. Some of the symptomatic data
were gathered by telephone consultation only, using the mea-
sures outlined above. Telephone reviews did not permit uri-
nary biomarker data to be collected at all consultations.
The East Central London Regional Ethics Committee
(REC1) (Ref: 11/H0721/7) provided ethical approval for data
collection.
Statistics
We used the IBM SPSS version 25 (IBM, New York) for
analyses. The data were tested for normality using Q-Q plots.
A close linear relationship between the measured variables
and the theoretical Z-scores existed and so the data were suit-
able for parametric analysis. We analysed the differences over
the three assessment points using a repeated measures
ANOVA. Mauchly’s test was used and common variance
was not violated.
Results
The unplanned cessation of treatment occurred in 221 patients
(female = 210; male = 11) of the 1035 active patients at the
service, with a mean age of 56 years (range = 19–92; SD =
17.81). Sixty-six per cent of the women were post-menopaus-
al. They had experienced treatment-resistant, painful lower
urinary tract symptoms (LUTS) for a mean of 6 years (SD =
7) prior to presentation at this centre. They had attended the
centre for an average of seven clinic visits (SD = 6) over a
mean of 1.7 years (SD = 2), and all 1035 active patients were
being treated with antibiotics with regular trials of cessation.
One hundred and ninety-nine patients (90%; female = 188;
male = 9) reported deterioration in their symptoms after stop-
ping treatment. Thus, 21 did not report deterioration (10%;
female = 19; male = 2). We collected data on 192 (97%) of
those who deteriorated. The other seven were unavailable to
provide the minimum data set of symptom measures at three
assessments. Eight hundred and fourteen patients on our
books did not have their treatment interfered with during the
4-week clinic suspension as they were either not due an ap-
pointment during this period or some managed to renew their
prescription from the GP or private gynaecologist.
Patients had been assessed an average of 58 days (SD = 49)
before clinic closure. The service was closed for 5 weeks and
the patients were first reviewed an average of 68 days (SD =
38) after the closure. Their last review, within a year of the
suspension, was a mean of 284 days after clinic closure (SD
=76).
The results of the statistical analysis are reported in Table 1.
There was an increase in symptoms after cessation followed
by recovery in the wake of treatment reinstatement (F = 33;
df = 2; p < 0.001). Figure 1 illustrates the symptom response,
including data from the last patient review (mean = 353 days;
SD = 70; female = 21; df = 3; p < 0.001). Symptom scores in-
creased after antibiotics were stopped, but after the antibiotic
regime was recommenced, symptom scores fell to levels re-
ported prior to the suspension. Figure 1 includes a fourth data
point from the most recent assessment, typically conducted by
telephone and therefore not accompanied by urinalysis data.
Because of geographical dispersion and use of telephone
review, urinalysis data were collected less often than symptom
measures. Overall, urinalysis data were available for 132
Table 1 Results of repeated measures ANOVA comparing the variables
collected at the three assessments
Variable Df F Significance
Total symptoms score 2 33.228 0.000
Urgency symptoms 2 11.301 0.000
Stress urinary incontinence symptoms 2 4.282 0.014
Voiding symptoms 2 11.080 0.000
Pain symptoms 2 39.779 0.000
24-h frequency 2 1.008 0.366
24-h incontinence 2 3.795 0.023
Log10 wbc 2 3.713 0.026
Epithelial cell count 2 5.855 0.003
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Fig. 1 Mean total symptom score before cessation, when off treatment
and following reintroduction
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patients (66%) before cessation, 130 patients after cessation
(65%) and 122 (61%) after treatment reintroduction. Figure 2
plots the pyuria count before cessation, when off treatment
and following reintroduction. There was an increase in urinary
leucocyte expression after treatment cessation and a commen-
surate decrease after reinstating treatment (F = 3.7; df = 2; p =
0.026).
Figure 3 provides a similar analysis of the urothelial cell
counts at different time points. Urothelial cell expression mir-
rored changes in symptom scores and urinary leucocyte num-
bers (F = 6.0; df = 2; p = 0.003). Twenty-four-hour frequency
did not change over the series (F = 1; df = 2; p = 0.4) although
24-h incontinence worsened off treatment (F = 4.0; df = 2; p =
0.003). Menopausal status did not predict symptom scores,
pyuria or epithelial cell counts.
Urine cultures were obtained at the first three time points,
but only 20 (15%) were positive before treatment cessation,
24 (18%) after stopping and 25 (20%) after restarting
treatment.
Eleven patients needed admission to hospital during the
clinic closure and these were classified as SAEs in line with
ICHGCP criteria [17]. Admission indications are summarised
in Table 2. With one exception, these patients had not experi-
enced any hospital admission for UTI-associated SAEs whilst
receiving treatment from this service. The exception was one
patient who previously required admission following interrup-
tion of the management regimen as part of our treatment
protocol.
Discussion
These results support the hypothesis that treating painful
LUTS with long-term antimicrobial courses is effective.
These data support a mounting body of evidence [8, 9] that
painful LUTSmay have an infectious aetiology when dipstick
and microbiological culture results do not indicate disease.
The standard laboratory tests used to diagnose infection were
positive only in a small proportion of the clinic’s symptomatic
population (< 20%). This result is not surprising as we do not
use MSU cultures to initiate treatment, and the insensitivity of
urine culture is now well recognised [8].
An unplanned cessation of treatment in an unselected
group of patients with chronic painful LUTS managed with
protracted antimicrobial courses was coincident with a mea-
surable deterioration in symptoms. The reintroduction of the
original treatment regimen was associated with improvement.
Only 24-h urinary frequency was unaffected. Arguing against
a mere placebo effect or a by-product of the stress induced by
the clinic suspension, the inflammatory biomarker pyuria mir-
rored the rise and fall of symptoms in these patients. Similarly,
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Table 2 Hospitalised patients with SAEs in association with treatment
cessation
No. of patients
(n = 11)
Description of SAEs and management
1 Paraplegia due to activation of autoimmune vasculitis
secondary to urosepsis. Treated with cycles of IV
methylprednisolone and cyclophosphamide; UTI
remains difficult to manage
1 Admitted with urosepsis and CT evidence of right
renal abscess. Required 6 weeks of IV antibiotic
treatment
5 Admitted with acute UTI treated with a single-dose IV
antibiotic treatment and 5 days of oral antibiotics
after which UTI recurred
2 Reactivation of systemic lupus erythematous (SLE)
2 Worsening of multiple sclerosis (MS) symptoms and
CISC for retention
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shed urothelial cell counts, which are known to reflect a host
innate response to inflammation, moved in concert with the
other variables, thus supporting a growing awareness of their
ability to reflect the disease process [16, 18, 19].
A subset of the patients was hospitalised during the sus-
pension period, and the underlying reasons for admission
highlight worsening urinary infection, including pyelonephri-
tis and urosepsis, in the face of antibiotic withdrawal. These
events point to potentially significant consequences when pa-
tients receiving antibiotic therapy for presumed chronic infec-
tion have their treatment suddenly withdrawn without access
to treatment reinstatement. It should be noted that all but one
of these patients had remained free of hospital admissions
whilst under the care of the service and receiving treatment.
To date, a limited number of RCTs support longer-term
antibiotic treatment for painful LUTS caused by chronic in-
fection [21–23]. The current data are not from an RCT, but
they resulted from a randomwithdrawal of treatment followed
by reinstating the same treatment. These circumstances pro-
vide credible observational data from a cross-over process. As
well as corroborating the earlier RCTs, they are in agreement
with our own previous observational data demonstrating im-
provements associated with treatment [9]. Our earlier paper
also reported high relapse rates related to planned trials with-
out treatment. These data suggest that presumed chronic in-
fection may require much longer antibiotic courses than are
recommended for other urological infections. The next step is
a RCT using these data as proof of concept.
The principal limitation of this study is the lack of corrob-
orative microbiological data to compliment the existing vari-
ables that we report. Our research programme and others have
demonstrated the insensitivity of routine urine culture [7,
20–23], and treatment in the clinical service has not been
contingent on routine culture evidence of UTI. In fact, our
recent work shows that the MSU culture cannot distinguish
this sort of patient from healthy controls, whereas a genomic
analysis demonstrates clear differences (Sathiananthamoorthy
et al., 2018, Journal of Clinical Microbiology JCM01452-
18R1 In Press) [24]. Nonetheless, we recognise that the ab-
sence of MSU culture data will be contentious for many
readers. More sensitive urinalysis methods have been reported
in the literature, but their clinical application has yet to be
evaluated [7, 25].
Pyuria, however, is a well-established and independent
biomarker of UTI and is not subject to the same bias as
patient-reported symptoms. Once a staple of general clinical
practice, fresh urine microscopy is an easy method, but it may
be difficult to reintroduce this into ordinary healthcare.
However, there are automated cell counters that are not
expensive, which could be adapted to this role. We did not
collect data on vaginal oestrogen use in post-menopausal
women. Oestrogen replacement is not known to affect pyuria
counts and we failed to see an effect during observational work.
Another limitation is that this study is not a clinical trial,
though an RCT is being planned. However, the unique cir-
cumstances allowed us to generate data similar to that pro-
duced in cross-over studies, providing a rare opportunity to
test our hypothesis.
Finally, only two thirds of patients generated urinalysis
data, with the potential to generate selection bias. During nor-
mal clinic service, patients on telephone review had lower
symptom scores than those attending in person for urinalysis
(t = −3.2, p = 0.002, 95% CI of difference = −4.8 to −1.1),
indicating more stable disease permitting remote surveillance.
This was also the case after the prescribing restrictions were
lifted and normal service resumed (t = −4.9, p < 0.001, 95%
CI of difference = −5.9 to −2.5). By contrast, during the sus-
pension there was no difference between symptom scores
comparing those who attended for face-to-face review and
urinalysis with those who were reviewed by telephone (t =
−0.84, p = 0.4, 95% CI of difference = −2.4 to +1.0). Thus, it
is less likely that the data were confounded by a selection bias.
The UK National Institute for Health and Care Excellence
(NICE) has generated guidelines for the management of acute
UTI, which limits antibiotic prescriptions to 14 days. The
majority of patients in this study had failed to respond to
standard antibiotic treatment and other recommended inter-
ventions for painful LUTS, prior to referral to this service,
and a significant proportion of those referred for treatment
came from other tertiary units. NICE has acknowledged a
guideline deficit for patients affected by complicated UTI by
publishing a Bplaceholder^ statement, employed to identify a
knowledge gap [10]. It is noteworthy that the treatment of
acute UTI using recommended antibiotic prescribing guide-
lines is associated with a 25%–35% microbiological and
symptomatic failure rate [26]. These data, and the results of
our work, demonstrate the need for further research into the
management of UTI and for existing guidelines on UTI to be
urgently reviewed. It is our hope that clinicians will recognise
the challenges that these patients pose in their own practices
and that this will galvanise efforts to advance our knowledge
in this neglected area of medicine.
While widespread concern about antimicrobial resis-
tance (AMR) makes stewardship policies imperative, a
one-size-fits-all approach may be equally unhelpful.
Long-term antimicrobials should not be withheld when
they are necessary (as is the case, for example, in tuber-
culosis patients). This is particularly true when patients
are treated in a consultant-led clinical setting, subject to
additional governance processes, careful monitoring and
individualised therapy.
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